Blood Work Monitoring

Overview

Blood work is the most objective tool available for assessing the impact of peptide protocols on the body. Subjective observations — energy levels, sleep quality, recovery speed — are valuable but inherently biased. Laboratory markers provide quantifiable data points that reveal what is happening beneath the surface, including changes that may not produce noticeable symptoms until they become significant.

Every peptide protocol should include at minimum three blood draws: a pre-protocol baseline, a mid-protocol check, and a post-protocol follow-up during the washout period. This three-point framework establishes a personal reference range, identifies emerging trends, and confirms that the body has returned to its pre-protocol state after discontinuation.

This article outlines which markers to request, when to schedule draws, how testing requirements vary by compound category, and basic interpretation guidelines.

Compounds Involved

Blood work monitoring applies to all peptide protocols. The specific markers emphasized depend on the compound category:

Protocol Structure

The Universal Panel

Regardless of which peptides are being used, every researcher should establish these baseline markers before any protocol begins:

Tier 1 — Essential (every protocol):

• Complete Blood Count (CBC) with differential
• Comprehensive Metabolic Panel (CMP) — includes liver enzymes (AST, ALT), kidney function (BUN, creatinine, eGFR), electrolytes, glucose
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• C-Reactive Protein (CRP) — systemic inflammation marker
• Fasting glucose and fasting insulin

Tier 2 — Recommended (especially for GH or metabolic protocols):

• IGF-1 (Insulin-like Growth Factor 1) — primary indicator of growth hormone activity
• HbA1c (glycated hemoglobin) — 3-month average blood sugar
• Thyroid panel (TSH, free T3, free T4)
• Vitamin D (25-hydroxy)
• Homocysteine

Tier 3 — Advanced (for longevity or extended protocols):

• DHEA-S
• Cortisol (morning, fasted)
• Sex hormones (total testosterone, free testosterone, estradiol) — particularly relevant if using GH secretagogues long-term
• Amylase and lipase (if using GLP-1 agonists)
• Ferritin and iron panel
• High-sensitivity CRP (hs-CRP)

Testing Schedule

Standard Protocol (8–12 weeks)

Extended Protocol (12+ weeks)

GLP-1 Agonist Protocols

GLP-1 receptor agonists (Semaglutide, Tirzepatide) warrant more frequent metabolic monitoring due to their direct effects on glucose metabolism and pancreatic function:

• Baseline: Full panel including amylase, lipase, HbA1c
• Week 4: Fasting glucose, fasting insulin, lipase
• Week 8: Full metabolic recheck
• Every 8 weeks during extended use
• Post-discontinuation: HbA1c at 8 and 16 weeks (reflects 3-month glucose average)

Practical Considerations for Blood Draws

Fasting requirements. Most panels require 10-12 hours of fasting. Schedule morning draws. Water is permitted and encouraged to improve vein accessibility.

Timing relative to doses. For GH secretagogues, draw blood before the morning dose, not after. Post-dose IGF-1 readings can be artificially elevated and do not reflect true baseline secretion. For BPC-157 and similar non-hormonal peptides, dose timing relative to the draw is less critical.

Consistency matters. Use the same lab for all draws when possible. Reference ranges and testing methodologies vary between laboratories, which can introduce apparent changes that are actually inter-lab variability.

Cost management. Direct-to-consumer lab services (such as those offering self-ordered panels) can significantly reduce costs compared to physician-ordered labs processed through insurance. A comprehensive Tier 1 + Tier 2 panel typically costs between $100 and $250 through these services.

Important Considerations

A single out-of-range value is not necessarily alarming. Lab results fluctuate based on hydration, recent exercise, sleep quality, stress, and dozens of other variables. A single elevated liver enzyme reading does not automatically indicate liver damage — but it does warrant a retest in 2-4 weeks. Trends across multiple draws are far more informative than isolated values.

Know your personal baseline, not just the reference range. Laboratory reference ranges are population-level statistics. Your individual normal may sit at the high or low end of the range. This is why a pre-protocol baseline is essential — it establishes your personal reference point, making meaningful deviations detectable.

IGF-1 is the primary marker for GH secretagogue monitoring. Direct GH testing is unreliable due to the pulsatile nature of growth hormone secretion. IGF-1, produced by the liver in response to GH, provides a stable 24-hour average indicator of growth hormone activity. Elevated IGF-1 confirms that the secretagogue is stimulating GH release. Excessively elevated IGF-1 (significantly above the age-adjusted reference range) warrants dose reduction.

Liver enzymes deserve attention. AST and ALT are the primary markers of hepatic stress. While peptides are generally considered to have low hepatotoxicity compared to oral compounds, any protocol involving multiple compounds, alcohol consumption, or pre-existing liver conditions should include regular liver enzyme monitoring.

Share results with a healthcare provider. While self-ordered labs empower individual monitoring, interpretation of complex panels benefits from medical expertise. Establishing a relationship with a provider who is aware of your research activities allows for informed oversight without judgment.

Keep a lab history file. Store all lab results in a single location — digital or physical — organized chronologically. This historical record becomes increasingly valuable over time, allowing you to identify long-term trends and compare across different protocols. See Research Documentation Protocol for organizational frameworks.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Laboratory results should be interpreted by a qualified healthcare provider. Peptides discussed here are research compounds and may not be approved for human use in all jurisdictions. Individual responses vary, and the information presented here reflects general monitoring principles rather than personalized medical guidance.